User profiles for Jean-Yves Reginster

JEAN YVES REGINSTER

PROFESSEUR DE SANTE PUBLIQUE UNIVERSITE DE LIEGE
Verified email at uliege.be
Cited by 106751

Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature

…, O Bruyère, F Richy, C Dardennes, JY Reginster - JBJS, 2004 - journals.lww.com
Background: Total hip and total knee arthroplasties are well accepted as reliable and suitable
surgical procedures to return patients to function. Health-related quality-of-life instruments …

Osteoporosis: a still increasing prevalence

JY Reginster, N Burlet - Bone, 2006 - Elsevier
It is estimated that over 200 million people worldwide have osteoporosis. The prevalence of
osteoporosis is continuing to escalate with the increasingly elderly population. The major …

Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes

J Slomian, G Honvo, P Emonts, JY Reginster… - Women's …, 2019 - journals.sagepub.com
Introduction: The postpartum period represents the time of risk for the emergence of maternal
postpartum depression. There are no systematic reviews of the overall maternal outcomes …

[HTML][HTML] Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

…, R Prince, GA Gaich, JY Reginster… - New England journal …, 2001 - Mass Medical Soc
Background Once-daily injections of parathyroid hormone or its amino-terminal fragments
increase bone formation and bone mass without causing hypercalcemia, but their effects on …

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial

JY Reginster, R Deroisy, LC Rovati, RL Lee, E Lejeune… - The Lancet, 2001 - thelancet.com
Background Treatment of osteoarthritis is usually limited to short-term symptom control. We
assessed the effects of the specific drug glucosamine sulphate on the long-term progression …

[HTML][HTML] Effect of risedronate on the risk of hip fracture in elderly women

…, JM Kaufman, CH Chesnut, JY Reginster - New England journal …, 2001 - Mass Medical Soc
Background Risedronate increases bone mineral density in elderly women, but whether it
prevents hip fracture is not known. Methods We studied 5445 women 70 to 79 years old who …

[HTML][HTML] The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

…, R Rizzoli, HK Genant, JY Reginster - … England Journal of …, 2004 - Mass Medical Soc
Background Osteoporotic structural damage and bone fragility result from reduced bone
formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally …

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study

JY Reginster, E Seeman… - The journal of …, 2005 - academic.oup.com
Background: Strontium ranelate, a new oral drug shown to reduce vertebral fracture risk in
postmenopausal women with osteoporosis, was studied in the Treatment of Peripheral …

[HTML][HTML] Romosozumab in postmenopausal women with low bone mineral density

…, BL Langdahl, JY Reginster… - … England Journal of …, 2014 - Mass Medical Soc
Background Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal
antibody romosozumab binds to sclerostin and increases bone formation. Methods In a …

[HTML][HTML] Health outcomes of sarcopenia: a systematic review and meta-analysis

C Beaudart, M Zaaria, F Pasleau, JY Reginster… - PloS one, 2017 - journals.plos.org
Objective The purpose of this study was to perform a systematic review to assess the short-,
middle- and long-term consequences of sarcopenia. Methods Prospective studies assessing …